Executive Summary
Localization is the structural story
Decision 1165 targets domestic drug supply at 80% of demand and 70% of market value by 2030 [Decision 1165 2023]; locally produced API reaches a more modest 20% share. Circular 40/2025/TT-BYT explicitly rewards EU-GMP-certified domestic supply in hospital tenders [MoH 2025], converting the certification race into pricing power. The 2025-27 window decides which domestic majors lock in tender share before Tier-1 lot competition stabilises.
Biosimilars open the second leg
Celltrion launched Remsima (infliximab) and Herzuma (trastuzumab) into Vietnam in 2024-25 [Celltrion 2025]. Nanogen's Stimus (darbepoetin alfa biosimilar) is in late-stage hospital trials [Nanogen 2025]. With biologics at ~USD 7.3 bn within the broader pharma value chain [Medpath 2025] and ASP discounts of 50-70% versus reference biologics [InsightAce 2025], biosimilar penetration becomes the 2027-30 margin lever for both ETC tender wins and BHYT cost containment.
Demand backbone: demographics, coverage, spend
Vietnam's 102m-person economy expands at 7%-plus through the forecast window [IMF WEO 2026], with health spending and BHYT coverage compounding on top. Pharma spend per capita sits near USD 80 in 2025 [Kira estimates] — well below Thailand and Malaysia peers, and the convergence path is the underlying demand pull.
Population & ageing
Vietnam's population reached ~102m in 2025 [GSO 2025], with 14% over 60 and rising to ~20% by 2035 [GSO 2025]. The ageing curve translates directly into chronic-disease prescription volumes — diabetes, cardiovascular, oncology — the same therapy windows where biosimilar entry is now economically meaningful.
BHYT coverage
BHYT (compulsory health insurance) covers ~93% of the population [VSS 2024], anchoring the ETC channel. The 2025 abolition of hospital-rank distinction in drug-use eligibility [Circular 37/2024 2024] expanded access to higher-tier therapies at lower-tier facilities — the demand pull for biosimilars and high-end generics widens correspondingly.
Spend trajectory
Total health spend tracked 6%+ of GDP in 2025 [Kira estimates from GSO + MoH bulletins]. Pharma spend per capita rises to ~USD 110 by 2030 in our base case [Kira estimates], driven by ETC formulary expansion plus OTC retail consolidation. The relative-price tailwind versus brand-imports compresses; volume becomes the dominant growth lever.